Download PDF
Semin Liver Dis 2019; 39(03): 354-368
DOI: 10.1055/s-0039-1687823
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Retreatment of Hepatitis C Virus-Infected Patients with Direct-Acting Antiviral Failures

Jean-Michel Pawlotsky
1   Department of Virology, National Reference Center for Viral Hepatitis B, C and D, Université Paris-Est, Hôpital Henri Mondor, Créteil, France
2   Research team “Viruses, Hepatology, Cancers”, INSERM U955, Créteil, France
› Author Affiliations
Further Information

Publication History

Publication Date:
30 April 2019 (online)

    Permissions and Reprints

Abstract

The treatment of chronic hepatitis C virus (HCV) infection has considerably evolved with the development of safe and well-tolerated combinations of direct-acting antiviral (DAA) drugs yielding high rates of infection cure. However, some patients fail to achieve a sustained virological response while receiving the most recent DAA combinations. Several waves of treatment failures have occurred concomitantly to the use of different drug combinations. The outcome of their retreatment strongly depends on the DAA(s) received and the retreatment regimen(s) available. This article discusses virological failure rates with the successive waves of HCV combination regimens, the reasons for failure, the role of HCV resistance, and current retreatment options. The triple combination of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks is the first-line retreatment strategy in patients previously exposed to DAAs. Difficult-to-retreat patients may benefit from the combination of sofosbuvir plus glecaprevir/pibrentasvir and/or the addition of ribavirin and/or longer retreatment duration.

Keywords

hepatitis C virus - direct-acting antiviral drugs - resistance - virological failure - retreatment
 

  • References

  • 1 Nahon P, Bourcier V, Layese R. , et al; ANRS CO12 CirVir Group. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology 2017; 152 (01) 142.e2-156.e2
    PubMedGoogle Scholar
  • 2 European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018. J Hepatol 2018; 69 (02) 461-511
    CrossrefPubMedGoogle Scholar
  • 3 AASLD. Available at: https://www.hcvguidelines.org . Accessed January 9, 2019
    PubMed
  • 4 WHO. Available at: http://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/ . Accessed January 9, 2019
    PubMed
  • 5 Pawlotsky JM. Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology 2016; 151 (01) 70-86
    CrossrefPubMedGoogle Scholar
  • 6 Kwo P, Gitlin N, Nahass R. , et al. Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study. Hepatology 2016; 64 (02) 370-380
    CrossrefPubMedGoogle Scholar
  • 7 Lawitz E, Matusow G, DeJesus E. , et al. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2). Hepatology 2016; 64 (02) 360-369
    CrossrefPubMedGoogle Scholar
  • 8 Buti M, Calleja JL, Lens S. , et al. Simeprevir in combination with sofosbuvir in treatment-naïve and -experienced patients with hepatitis C virus genotype 4 infection: a Phase III, open-label, single-arm study (PLUTO). Aliment Pharmacol Ther 2017; 45 (03) 468-475
    CrossrefPubMedGoogle Scholar
  • 9 Poordad F, Schiff ER, Vierling JM. , et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology 2016; 63 (05) 1493-1505
    CrossrefPubMedGoogle Scholar
  • 10 Wyles DL, Ruane PJ, Sulkowski MS. , et al; ALLY-2 Investigators. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015; 373 (08) 714-725
    CrossrefPubMedGoogle Scholar
  • 11 Nelson DR, Cooper JN, Lalezari JP. , et al; ALLY-3 Study Team. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 2015; 61 (04) 1127-1135
    CrossrefPubMedGoogle Scholar
  • 12 Leroy V, Angus P, Bronowicki JP. , et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3+). Hepatology 2016; 63 (05) 1430-1441
    CrossrefPubMedGoogle Scholar
  • 13 Afdhal N, Zeuzem S, Kwo P. , et al; ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370 (20) 1889-1898
    CrossrefPubMedGoogle Scholar
  • 14 Afdhal N, Reddy KR, Nelson DR. , et al; ION-2 Investigators. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370 (16) 1483-1493
    CrossrefPubMedGoogle Scholar
  • 15 Kowdley KV, Gordon SC, Reddy KR. , et al; ION-3 Investigators. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370 (20) 1879-1888
    CrossrefPubMedGoogle Scholar
  • 16 Naggie S, Cooper C, Saag M. , et al; ION-4 Investigators. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015; 373 (08) 705-713
    CrossrefPubMedGoogle Scholar
  • 17 Abergel A, Metivier S, Samuel D. , et al. Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection. Hepatology 2016; 64 (04) 1049-1056
    CrossrefPubMedGoogle Scholar
  • 18 Abergel A, Asselah T, Metivier S. , et al. Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study. Lancet Infect Dis 2016; 16 (04) 459-464
    CrossrefPubMedGoogle Scholar
  • 19 Feld JJ, Jacobson IM, Hézode C. , et al; ASTRAL-1 Investigators. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 2015; 373 (27) 2599-2607
    CrossrefPubMedGoogle Scholar
  • 20 Foster GR, Afdhal N, Roberts SK. , et al; ASTRAL-2 Investigators; ASTRAL-3 Investigators. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 2015; 373 (27) 2608-2617
    CrossrefPubMedGoogle Scholar
  • 21 Curry MP, O'Leary JG, Bzowej N. , et al; ASTRAL-4 Investigators. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 2015; 373 (27) 2618-2628
    CrossrefPubMedGoogle Scholar
  • 22 Wyles D, Bräu N, Kottilil S. , et al; ASTRAL-5 Investigators. Sofosbuvir and velpatasvir for the treatment of hepatitis C virus in patients coinfected with human immunodeficiency virus type 1: an open-label, Phase 3 study. Clin Infect Dis 2017; 65 (01) 6-12
    CrossrefPubMedGoogle Scholar
  • 23 Feld JJ, Kowdley KV, Coakley E. , et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370 (17) 1594-1603
    CrossrefPubMedGoogle Scholar
  • 24 Zeuzem S, Jacobson IM, Baykal T. , et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370 (17) 1604-1614
    CrossrefPubMedGoogle Scholar
  • 25 Andreone P, Colombo MG, Enejosa JV. , et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology 2014; 147 (02) 359.e1-365.e1
    PubMedGoogle Scholar
  • 26 Ferenci P, Bernstein D, Lalezari J. , et al; PEARL-III Study; PEARL-IV Study. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014; 370 (21) 1983-1992
    CrossrefPubMedGoogle Scholar
  • 27 Dore GJ, Conway B, Luo Y. , et al. Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: the MALACHITE-I/II trials. J Hepatol 2016; 64 (01) 19-28
    CrossrefPubMedGoogle Scholar
  • 28 Poordad F, Hezode C, Trinh R. , et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370 (21) 1973-1982
    CrossrefPubMedGoogle Scholar
  • 29 Feld JJ, Moreno C, Trinh R. , et al. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks. J Hepatol 2016; 64 (02) 301-307
    CrossrefPubMedGoogle Scholar
  • 30 Manns M, Pol S, Jacobson IM. , et al; HALLMARK-DUAL Study Team. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet 2014; 384 (9954): 1597-1605
    CrossrefPubMedGoogle Scholar
  • 31 Wei L, Zhang M, Xu M. , et al. A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin. J Gastroenterol Hepatol 2016; 31 (11) 1860-1867
    CrossrefPubMedGoogle Scholar
  • 32 Zeuzem S, Ghalib R, Reddy KR. , et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med 2015; 163 (01) 1-13
    CrossrefPubMedGoogle Scholar
  • 33 Rockstroh JK, Nelson M, Katlama C. , et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV 2015; 2 (08) e319-e327
    CrossrefPubMedGoogle Scholar
  • 34 Kwo P, Gane EJ, Peng CY. , et al. Effectiveness of elbasvir and grazoprevir combination, with or without ribavirin, for treatment-experienced patients with chronic hepatitis C infection. Gastroenterology 2017; 152 (01) 164-175.e4
    CrossrefPubMedGoogle Scholar
  • 35 Krishnan P, Schnell G, Tripathi R. , et al. Pooled resistance analysis in HCV genotype 1–6-infected patients treated with glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials. J Hepatol 2017; 66 (Suppl. 01) S500
    PubMedGoogle Scholar
  • 36 Bourlière M, Gordon SC, Flamm SL. , et al; POLARIS-1 and POLARIS-4 Investigators. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med 2017; 376 (22) 2134-2146
    CrossrefPubMedGoogle Scholar
  • 37 Jacobson IM, Lawitz E, Gane EJ. , et al. Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 Phase 3 randomized trials. Gastroenterology 2017; 153 (01) 113-122
    CrossrefPubMedGoogle Scholar
  • 38 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu. EASL recommendations on treatment of hepatitis C 2016. J Hepatol 2017; 66 (01) 153-194
    CrossrefPubMedGoogle Scholar
  • 39 Fourati S, Rodriguez C, Hézode C. , et al. Frequent antiviral treatment failures in patients infected with hepatitis C virus genotype 4, subtype 4r. Hepatology 2019; 69: 513-523
    CrossrefPubMedGoogle Scholar
  • 40 Sorbo MC, Cento V, Di Maio VC. , et al. Hepatitis C virus drug resistance associated substitutions and their clinical relevance: update 2018. Drug Resist Updat 2018; 37: 17-39
    CrossrefPubMedGoogle Scholar
  • 41 Charlton M, Everson GT, Flamm SL. , et al; SOLAR-1 Investigators. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015; 149 (03) 649-659
    CrossrefPubMedGoogle Scholar
  • 42 Pawlotsky JM. Hepatitis C virus genetic variability: pathogenic and clinical implications. Clin Liver Dis 2003; 7 (01) 45-66
    CrossrefPubMedGoogle Scholar
  • 43 Gane EJ, Metivier S, Nahass R. , et al. The emergence of NS5B resistance associated substitution S282T after sofosbuvir-based treatment. Hepatol Commun 2017; 1 (06) 538-549
    CrossrefPubMedGoogle Scholar
  • 44 Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol 2016; 64 (02) 486-504
    CrossrefPubMedGoogle Scholar
  • 45 Lenz O, Verbinnen T, Fevery B. , et al. Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies. J Hepatol 2015; 62 (05) 1008-1014
    CrossrefPubMedGoogle Scholar
  • 46 Zeuzem S, Mizokami M, Pianko S. , et al. NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome. J Hepatol 2017; 66 (05) 910-918
    CrossrefPubMedGoogle Scholar
  • 47 Zeuzem S, Mizokami M, Pianko S. , et al. Prevalence of pretreatment NS5A resistance associated variants in genotype 1 patients across different regions using deep sequencing and effect on treatment outcome with LDV/SOF. Hepatology 2015; 62 (Suppl. 01) 254A
    CrossrefPubMedGoogle Scholar
  • 48 McPhee F, Hernandez D, Zhou N. , et al. Pooled analysis of HCV genotype 1 resistance-associated substitutions in NS5A, NS3 and NS5B pre-and post-treatment with 12 weeks of daclatasvir, asunaprevir and beclabuvir. Antivir Ther 2018; 23 (01) 53-66
    PubMedGoogle Scholar
  • 49 Sezaki H, Suzuki F, Hosaka T. , et al. The efficacy and safety of dual oral therapy with daclatasvir and asunaprevir for genotype 1b in Japanese real-life settings. Liver Int 2017; 37 (09) 1325-1333
    CrossrefPubMedGoogle Scholar
  • 50 Sarrazin C, Dvory-Sobol H, Svarovskaia ES. , et al. The prevalence and the effect of HCV NS5A resistance associated variants in subjects with compensated cirrhosis treated with ledipasvir/sofosbuvir +/− RBV. J Hepatol 2015; 62 (Suppl. 02) S620
    PubMedGoogle Scholar
  • 51 Sarrazin C, Sulkowski MS, Krishnan P. , et al. Effect of baseline resistance-associated variants on SVR with the 3D regimen with and without RBV in GT1a and GT1b-infected patients. J Hepatol 2016; 64 (Suppl. 01) S214
    PubMedGoogle Scholar
  • 52 Jacobson I, Asante-Appiah E, Wong P. , et al. Prevalence and impact of baseline NS5A resistance-associated variants (RAVs) on the efficacy of elbasvir/grazoprevir (EBR/GZR) against GT1a infection. Hepatology 2015; 62: 1393A
    PubMedGoogle Scholar
  • 53 Esteban R, Pineda JA, Calleja JL. , et al. Efficacy of sofosbuvir and velpatasvir, with and without ribavirin, in patients with hepatitis C virus genotype 3 infection and cirrhosis. Gastroenterology 2018; 155 (04) 1120.e4-1127.e4
    PubMedGoogle Scholar
  • 54 Svarovskaia ES, Gane E, Dvory-Sobol H. , et al. L159F and V321A sofosbuvir-associated hepatitis C virus NS5B substitutions. J Infect Dis 2016; 213 (08) 1240-1247
    CrossrefPubMedGoogle Scholar
  • 55 Krishnan P, Tripathi R, Schnell G. , et al. Pooled analysis of resistance in patients treated with ombitasvir/ABT-450/r and dasabuvir with or without ribavirin in Phase 2 and Phase 3 clinical trials. Hepatology 2014; 60 (Suppl.): 1134A
    PubMedGoogle Scholar
  • 56 Sullivan JC, De Meyer S, Bartels DJ. , et al. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Clin Infect Dis 2013; 57 (02) 221-229
    CrossrefPubMedGoogle Scholar
  • 57 Howe AY, Long J, Nickle D. , et al. Long-term follow-up of patients receiving boceprevir for treatment of chronic hepatitis C. Antiviral Res 2015; 113: 71-78
    CrossrefPubMedGoogle Scholar
  • 58 Dvory-Sobol H, Wyles D, Ouyang W. , et al. Long-term persistence of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir. J Hepatol 2015; 62 (Suppl. 02) S221
    PubMedGoogle Scholar
  • 59 Buti M, Lurie Y, Zakharova NG. , et al; SUCCESS Study Investigators. Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response. Hepatology 2010; 52 (04) 1201-1207
    CrossrefPubMedGoogle Scholar
  • 60 Black S, Pak I, Ingravallo P. , et al. Resistance analysis of virologic failures in hepatitis C genotype 1 infected patients treated with grazoprevir/elbasvir +/− ribavirin: the C-WORTHY study. J Hepatol 2015; 62 (Suppl. 02) S677
    PubMedGoogle Scholar
  • 61 Covert E, Hoffmann J, Comstock E. , et al. Retreatment with SOF/VEL/VOX in treatment-experienced patients with and without HIV: the RESOLVE study. Hepatology 2018; 68 (Suppl.): 346A
    PubMedGoogle Scholar
  • 62 Vermehren J, Stoehr A, Schulze J. , et al. Retreatment with voxilaprevir/velpatasvir/sofosbuvir in patients with chronic hepatitis C virus infection and prior DAA failure. Results from the German Hepatitis C Registry (DHC-R). Hepatology 2018; 68 (Suppl.): 401A
    CrossrefPubMedGoogle Scholar
  • 63 Llaneras J, Barciela MR, Lens S. , et al. Real-life effectiveness and safety of velpatasvir/sofosbuvir/voxilaprevir for previously DAA-treated patients with chronic hepatitis C. Hepatology 2018; 68 (Suppl.): 405A
    PubMedGoogle Scholar
  • 64 Bacon BR, Curry MP, Flamm SL. , et al. Sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) in care of chronic hepatitis C patients: clinical practice experience from the TRIO network. Hepatology 2018; 68 (Suppl.): 419A
    PubMedGoogle Scholar
  • 65 Belperio PS, Shahoumian T, Loomis T. , et al. Real-world effectiveness of sofosbuvir/velpatasvir/voxilaprevir in 573 treatment-experienced patients with hepatitis C genotypes 1 through 4. Hepatology 2018; 68 (Suppl.): 142A
    PubMedGoogle Scholar
  • 66 Hezode C, Guyader D, Nguyen-Khac E. , et al. Sofosbuvir + velpatasvir + voxilaprevir in DAA failure patients with cirrhosis. Final results of the French compassionate use program. Hepatology 2018; 68 (Suppl.): 374A
    CrossrefPubMedGoogle Scholar
  • 67 Vermehren J, Dietz J, Peiffer KH. , et al. Resistance analysis in direct-acting antiviral-experienced patients with chronic hepatitis C virus infection treated with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX). Results from the Frankfurt Resistance Database. Hepatology 2018; 68 (Suppl.): 397A
    CrossrefPubMedGoogle Scholar
  • 68 Backus LI, Belperio PS, Shahoumian T. , et al. Real-world impact of resistance-associated substitutions on retreatment after ledipasvir/sofosbuvir virologic failure in hepatitis C patients. Hepatology 2018; 68 (Suppl.): 348A
    PubMedGoogle Scholar
  • 69 Poordad F, Pol S, Asatryan A. , et al. Glecaprevir/pibrentasvir in patients with HCV genotype 1 or 4 and prior direct-acting antiviral treatment failure. Hepatology 2018; 67: 1253-1260
    CrossrefPubMedGoogle Scholar
  • 70 Sulkowski M, Lok AS, Willner IR. , et al. High efficacy of glecaprevir/pibrentasvir in patients with chronic HCV GT1 infection who failed prior treatment with NS5A inhibitor plus sofosbuvir regimens. Hepatology 2018; 68 (Suppl.): 141A
    CrossrefPubMedGoogle Scholar
  • 71 Uemura H, Uchida Y, Kouyama JI. , et al. Real-world efficacy of glecaprevir plus pibrentasvir for patients with HCV with or without prior DAA therapies: evaluation by deep sequencing for HCV strains with NS5A RAS. Hepatology 2018; 68 (Suppl.): 402A
    PubMedGoogle Scholar
  • 72 Wyles D, Weiland O, Yao B. , et al. Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection. J Hepatol 2018; 68 (Suppl. 01) S23
    PubMedGoogle Scholar
  • 73 Ng TI, Krishnan P, Pilot-Matias T. , et al. In vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS5A inhibitor pibrentasvir. Antimicrob Agents Chemother 2017; 61 (05) e02558-e16
    PubMedGoogle Scholar
  • 74 de Lédinghen V, Laforest C, Hézode C. , et al. Retreatment with sofosbuvir plus grazoprevir/elbasvir plus ribavirin of patients with hepatitis C virus genotype 1 or 4 who previously failed an NS5A- or NS3-containing regimen: the ANRS HC34 REVENGE Study. Clin Infect Dis 2018; 66 (07) 1013-1018
    CrossrefPubMedGoogle Scholar
  • 75 Lawitz E, Poordad F, Gutierrez JA. , et al. Short-duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: a randomized trial. Hepatology 2017; 65 (02) 439-450
    CrossrefPubMedGoogle Scholar
  • 76 Poordad F, Bennett M, Sepe TE. , et al. Ombitasvir/paritaprevir/r, dasabuvir and sofosbuvir treatment of patients with genotype 1 infection who failed a prior course of DAA therapy: the QUARTZ-I study. J Hepatol 2016; 64 (Suppl. 02) S767-S768
    PubMedGoogle Scholar
  • 77 Hézode C, Fourati S, Chevaliez S. , et al. Sofosbuvir-daclatasvir-simeprevir plus ribavirin in direct-acting antiviral-experienced patients with hepatitis C. Clin Infect Dis 2017; 64 (11) 1615-1618
    CrossrefPubMedGoogle Scholar